

Special Issue

Development of Broadly Protective Vaccines Against Respiratory Virus Infections

Message from the Guest Editors

Respiratory virus infections pose substantial health burdens globally; causing significant morbidity & mortality. Traditional vaccines offer varying degrees of success; however, their strain-specific protection & limited durability show the need for broadly protective vaccines. These vaccines aim to elicit cross-reactive immune responses that protect against multiple virus strains or species. This issue will highlight cutting-edge research & developments in broadly protective vaccines against respiratory viruses. We invite submissions on:

- Strategies for designing broadly protective or universal vaccines.
- Development & optimization of novel vaccine platforms & adjuvants that enhance scope & durability of protection.
- Characterization of cross-protective immune responses, such as broadly neutralizing antibodies, T-cell responses, & mucosal immunity.
- Preclinical & clinical evaluations of vaccine efficacy against diverse respiratory virus strains.
- Factors in developing broadly protective vaccines for vulnerable populations.
- Long-term safety, immunogenicity, & immune correlates of protection for broadly protective vaccine candidates.

We look forward to your valuable contributions.

Guest Editors

Dr. Noopur Bhatnagar

Center for Inflammation, Immunity and Infection, Institute for Biomedical Sciences, Georgia State University, Atlanta, GA 30302, USA
Prof. Dr. Jerry W. Simecka

Department of Pharmaceutical Sciences and UNTHSC Preclinical Services, University of North Texas System College of Pharmacy, University of North Texas Health Science Center, Fort Worth, TX, USA

Deadline for manuscript submissions

31 December 2026



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/244244

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).